Nigerian researcher and cloud security engineer, Innocent Opara, has conducted a pioneering systematic review that redefines the potential of artificial intelligence and cloud cybersecurity in transforming the diagnosis and treatment of rare genetic diseases.
Titled Integrating AI-Based Therapeutic Design and Cloud Cybersecurity for Rare Genetic Diseases: A Systematic Review, this study explores the integration of AI-driven therapeutic molecule design with robust cybersecurity measures to safeguard sensitive genomic information. The research establishes a distinctive interdisciplinary connection between biomedical advancements and digital security in contemporary medicine.
Opara’s review examined 208 peer-reviewed articles published from 2015 to 2025, chosen from an initial selection of over 1,000 studies sourced from databases including PubMed, Scopus, IEEE Xplore, SpringerLink, and Web of Science. Employing the PRISMA framework, he methodically evaluated the utilization of AI and cloud technologies in expediting discovery while tackling the ethical, technical, and security issues that arise alongside them.
The study highlights several pivotal AI technologies currently influencing the domain. Deep learning is utilized for phenotype-genotype mapping; generative adversarial networks are innovating new molecule designs; and natural language processing is analyzing biomedical literature on an unprecedented scale. Opara also emphasizes the emergence of federated learning—a model that facilitates decentralized, privacy-preserving data analysis among global research institutions.
Also Read: http://Bayelsa Reaffirms Commitment to Quality Healthcare Access
He remarked that AI-enhanced facial recognition systems like Face2Gene now surpass clinical assessments in diagnosing specific genetic syndromes based on facial characteristics. Nevertheless, he warned that these technologies are still vulnerable to threats such as adversarial attacks, data poisoning, and model inversion. “The potential of AI in medicine is immense,” Opara stated, “but without robust cyber defenses, that potential could become a significant risk for patients.”
In addition to technical advancements, the study highlights significant ethical issues such as informed consent, algorithmic bias, data ownership, and adherence to privacy regulations like the GDPR. Opara stressed that the rapid pace of innovation in genomic AI should never exceed the ethical and legal frameworks designed to safeguard patient rights. “We must ensure that precision medicine remains both precise and principled,” he stated.
The review also indicated that the rate of interdisciplinary collaboration in this field is increasing significantly. Over 230,000 studies related to AI and rare disease research were published in 2025 alone, indicating a global transition towards integrated computational health systems. Opara believes this increase signifies a growing acknowledgment of AI’s potential to address medical issues that conventional methods cannot solve.
His findings advocate for cloud systems that incorporate differential privacy, homomorphic encryption, and adversarial training—three sophisticated techniques that secure data during the training and processing of AI models. He contends that these technologies should be the cornerstone of next-generation healthcare cybersecurity.
Opara asserted that ethical governance must act as the “compass” for the responsible deployment of these systems. “Responsible AI in healthcare is not merely about quicker analysis; it is about trust, transparency, and the human lives represented by the data,” he remarked. His appeal emphasizes a new vision for global biomedical collaboration that harmonizes speed with security.
